Functionality of Dengue Virus Specific Memory T Cell Responses in Individuals Who Were Hospitalized or Who Had Mild or Subclinical Dengue Infection

PLoS Neglected Tropical Diseases

Volumn 9, Issue 4, 2015, Pages

  Jeewandara, Chandima ^a,b   Adikari, Thiruni N ^a   Gomes, Laksiri ^a   Fernando, Samitha ^a   Fernando, R H ^a   Perera, M K T ^a   Ariyaratne, Dinuka ^a   Kamaladasa, Achala ^a   Salimi, Maryam ^b   Prathapan, Shamini ^a   Ogg, Graham S ^b,c   Malavige, Gathsaurie Neelika ^a,b  

^a UNIVERSITY OF SRI JAYEWARDENEPURA   (Sri Lanka)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANZYME B; TUMOR NECROSIS FACTOR ALPHA; NS3 PROTEIN, FLAVIVIRUS; PEPTIDE; RNA HELICASE; SERINE PROTEINASE; VIRAL PROTEIN;

ADULT; ARTICLE; DENGUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNOLOGICAL MEMORY; MAJOR CLINICAL STUDY; MALE; SEROLOGY; SEROTYPE; T LYMPHOCYTE; CLASSIFICATION; CROSS REACTION; DENGUE VIRUS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SRI LANKA; VIROLOGY;

CROSS REACTIONS; CYTOKINES; DENGUE; DENGUE VIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC MEMORY; PEPTIDES; RNA HELICASES; SERINE ENDOPEPTIDASES; SRI LANKA; T-LYMPHOCYTES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84929484739     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003673     Document Type: Article

References (48)

1. Callaway E, Dengue fever climbs the social ladder. Nature. 2007;448:734–5. 17700664
2. WHO. Dengue guidelines for diagnosis, prevention and control. New edition ed. Southeast Asian Office of the WHO World Health Organisation; 2009.
3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. Epub 2013/04/09. doi: 10.1038/nature12060 23563266; PubMed Central PMCID: PMC3651993.
4. WHO, editor. Comprehensive guidelines for prevention and control of dengue fever and dengue haemorrhagic fever. SEARO, New Delhi, India: World Health Organization; 2011.
5. Thomas SJ, Endy TP, Critical issues in dengue vaccine development. Current opinion in infectious diseases. 2011;24(5):442–50. 21799408. doi: 10.1097/QCO.0b013e32834a1b0b
6. Halstead SB, Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine. 2013;31(41):4501–7. Epub 2013/07/31. doi: 10.1016/j.vaccine.2013.06.079 23896423.
7. Wilder-Smith A, Macary P, Dengue: challenges for policy makers and vaccine developers. Current infectious disease reports. 2014;16(5):404. Epub 2014/05/02. doi: 10.1007/s11908-014-0404-2 24781826.
8. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–65. Epub 2014/07/16. doi: 10.1016/S0140-6736(14)61060-6 25018116.
9. McArthur MA, Sztein MB, Edelman R, Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert review of vaccines. 2013;12(8):933–53. Epub 2013/08/30. doi: 10.1586/14760584.2013.815412 23984962; PubMed Central PMCID: PMC3773977.
10. Dong T, Moran E, Vinh Chau N, Simmons C, Luhn K, Peng Y, et al. High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PloS one. 2007;2(12):e1192. 18060049.
11. Moran E, Simmons C, Vinh Chau N, Luhn K, Wills B, Dung NP, et al. Preservation of a critical epitope core region is associated with the high degree of flaviviral cross-reactivity exhibited by a dengue-specific CD4+ T cell clone. Eur J Immunol. 2008;38(4):1050–7. 18383038. doi: 10.1002/eji.200737699
12. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol. 2006;176(6):3821–9. 16517753.
13. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(22):E2046–53. Epub 2013/04/13. doi: 10.1073/pnas.1305227110 23580623; PubMed Central PMCID: PMC3670335.
14. Malavige GN, Jeewandara C, Alles KM, Salimi M, Gomes L, Kamaladasa A, et al. Suppression of virus specific immune responses by IL-10 in acute dengue infection. PLoS neglected tropical diseases. 2013;7(9):e2409. Epub 2013/09/17. doi: 10.1371/journal.pntd.0002409 24040431; PubMed Central PMCID: PMC3764236.
15. Van Braeckel E, Desombere I, Clement F, Vandekerckhove L, Verhofstede C, Vogelaers D, et al. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. Vaccine. 2013;31(36):3739–46. Epub 2013/05/28. doi: 10.1016/j.vaccine.2013.05.021 23707169.
16. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 2009;183(12):7919–30. Epub 2009/11/26. doi: 10.4049/jimmunol.0803903 19933869; PubMed Central PMCID: PMC3374958.
17. Yamamoto T, Iwamoto N, Yamamoto H, Tsukamoto T, Kuwano T, Takeda A, et al. Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection. Journal of virology. 2009;83(11):5514–24. Epub 2009/03/20. doi: 10.1128/JVI.00145-09 19297503; PubMed Central PMCID: PMC2681982.
18. Ciuffreda D, Comte D, Cavassini M, Giostra E, Buhler L, Perruchoud M, et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. European journal of immunology. 2008;38(10):2665–77. Epub 2008/10/30. doi: 10.1002/eji.200838336 18958874.
19. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nature medicine. 2003;9(7):921–7. 12808447.
20. Guzman MG, Kouri G, Valdes L, Bravo J, Vazquez S, Halstead SB, Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Revista panamericana de salud publica = Pan American journal of public health. 2002;11(4):223–7. 12049030.
21. Mathew A, Rothman AL, Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunological reviews. 2008;225:300–13. 18837790. doi: 10.1111/j.1600-065X.2008.00678.x
22. Burke DS, Nisalak A, Johnson DE, Scott RM, A prospective study of dengue infections in Bangkok. The American journal of tropical medicine and hygiene. 1988;38(1):172–80. Epub 1988/01/01. 3341519.
23. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. The American journal of tropical medicine and hygiene. 2009;81(5):825–33. Epub 2009/10/29. doi: 10.4269/ajtmh.2009.08-0625 19861618; PubMed Central PMCID: PMC2835862.
24. van Panhuis WG, Gibbons RV, Endy TP, Rothman AL, Srikiatkhachorn A, Nisalak A, et al. Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers. The Journal of infectious diseases. 2010;202(7):1002–10. Epub 2010/08/27. doi: 10.1086/656141 20738205; PubMed Central PMCID: PMC2943243.
25. Moi ML, Lim CK, Chua KB, Takasaki T, Kurane I, Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcgammaR-expressing cells. PLoS neglected tropical diseases. 2012;6(2):e1536. Epub 2012/03/06. doi: 10.1371/journal.pntd.0001536 22389741; PubMed Central PMCID: PMC3289619.
26. Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, Lessler J, Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. BMC infectious diseases. 2012;12:233. Epub 2012/10/02. doi: 10.1186/1471-2334-12-233 23020074; PubMed Central PMCID: PMC3519720.
27. Rodrigo WW, Alcena DC, Kou Z, Kochel TJ, Porter KR, Comach G, et al. Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin Vaccine Immunol. 2009;16(2):285–7. 19038781. doi: 10.1128/CVI.00363-08
28. Sirivichayakul C, Sabchareon A, Limkittikul K, Yoksan S, Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand. Virology journal. 2014;11(1):48. Epub 2014/03/14. doi: 10.1186/1743-422X-11-48 24620925.
29. Malavige GN, McGowan S, Atukorale V, Salimi M, Peelawatta M, Fernando N, et al. Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses. Clin Exp Immunol. 2012;168(2):215–23. Epub 2012/04/05. doi: 10.1111/j.1365-2249.2012.04566.x 22471283; PubMed Central PMCID: PMC3390523.
30. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. Journal of immunological methods. 2002;260(1–2):157–72. Epub 2002/01/17. 11792386.
31. Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, et al. IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. British journal of cancer. 2010;102(4):727–30. 20087346. doi: 10.1038/sj.bjc.6605542
32. Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, Thao le TT, et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. Journal of virology. 2005;79(9):5665–75. 15827181.
33. Malavige GN, Jones L, Kamaladasa SD, Wijewickrama A, Seneviratne SL, Black AP, et al. Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PloS one. 2008;3(11):e3789. 19023425. doi: 10.1371/journal.pone.0003789
34. Appanna R, Huat TL, See LL, Tan PL, Vadivelu J, Devi S, Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia. Clin Vaccine Immunol. 2007;14(8):969–77. 17567768.
35. Weiskopf D, Sette A, T-cell immunity to infection with dengue virus in humans. Frontiers in immunology. 2014;5:93. Epub 2014/03/19. doi: 10.3389/fimmu.2014.00093 24639680; PubMed Central PMCID: PMC3945531.
36. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. The Journal of infectious diseases. 2000;181(1):2–9. doi: 10608744 10608744
37. Guzman MG, Alvarez M, Halstead SB, Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Archives of virology. 2013;158(7):1445–59. Epub 2013/03/09. doi: 10.1007/s00705-013-1645-3 23471635.
38. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, et al. An in-depth analysis of original antigenic sin in dengue virus infection. Journal of virology. 2011;85(1):410–21. Epub 2010/10/29. doi: 10.1128/JVI.01826-10 20980526; PubMed Central PMCID: PMC3014204.
39. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, Scott RM, et al. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. The American journal of tropical medicine and hygiene. 2003;68(2):191–202. 12641411.
40. Balmaseda A, Hammond SN, Perez L, Tellez Y, Saborio SI, Mercado JC, et al. Serotype-specific differences in clinical manifestations of dengue. The American journal of tropical medicine and hygiene. 2006;74(3):449–56. 16525106.
41. Sandberg JK, Fast NM, Nixon DF, Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J Immunol. 2001;167(1):181–7. Epub 2001/06/22. 11418647.
42. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, et al. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol. 2007;178(7):4112–9. Epub 2007/03/21. 17371966.
43. Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. Journal of virology. 2013;87(5):2693–706. Epub 2012/12/21. doi: 10.1128/JVI.02675-12 23255803; PubMed Central PMCID: PMC3571409.
44. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, et al. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS medicine. 2009;6(10):e1000171. Epub 2009/10/28. doi: 10.1371/journal.pmed.1000171 19859541; PubMed Central PMCID: PMC2762316.
45. Anderson KB, Gibbons RV, Thomas SJ, Rothman AL, Nisalak A, Berkelman RL, et al. Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS neglected tropical diseases. 2011;5(10):e1311. 21991398. doi: 10.1371/journal.pntd.0001311
46. Mansfield KL, Horton DL, Johnson N, Li L, Barrett AD, Smith DJ, et al. Flavivirus-induced antibody cross-reactivity. The Journal of general virology. 2011;92(Pt 12):2821–9. Epub 2011/09/09. doi: 10.1099/vir.0.031641-0 21900425; PubMed Central PMCID: PMC3352572.
47. Unni SK, Ruzek D, Chhatbar C, Mishra R, Johri MK, Singh SK, Japanese encephalitis virus: from genome to infectome. Microbes and infection / Institut Pasteur. 2011;13(4):312–21. Epub 2011/01/18. doi: 10.1016/j.micinf.2011.01.002 21238600.
48. Yamada K, Takasaki T, Nawa M, Yabe S, Kurane I, Antibody responses determined for Japanese dengue fever patients by neutralization and hemagglutination inhibition assays demonstrate cross-reactivity between dengue and Japanese encephalitis viruses. Clinical and diagnostic laboratory immunology. 2003;10(4):725–8. Epub 2003/07/11. 12853413; PubMed Central PMCID: PMC164242.